Inequities in access to biologic and synthetic DMARDs across 46 European countries
2013/03/07 by Polina Putrik, Sofia Ramiro, Sofía Ramiro +48 · 26 citations
Medicine · Immunology and Microbiology · #Rheumatoid Arthritis Research and Therapies #Biosimilars and Bioanalytical Methods #Medication Adherence and Compliance
paper · doi:10.1136/annrheumdis-2012-202603
Abstract
OBJECTIVES: We investigated access to biologic and synthetic disease modifying drugs (bDMARDs and sDMARDs) in patients with rheumatoid arthritis (RA) across Europe. METHODS: A cross-sectional study at national level was performed in 49 European countries. A questionnaire was sent to one expert, addressing the number of approved and reimbursed bDMARDs and sDMARDs, prices and co-payments, as well as acceptability of bDMARDs (barriers). Data on socio-economic welfare (gross domestic product per capita (GDP), health expenditure, income) were retrieved from web-based sources. Data on health status of RA patients were retrieved from an observational study. Dimensions of access (availability, affordability and acceptability) were correlated with the country's welfare and RA health status. RESULTS: In total, 46 countries (94%) participated. Six countries did not reimburse any of the five sDMARDs surveyed, and in ten countries no bDMARDs were reimbursed. While the price of annual treatment with an average sDMARD was never higher than GPD, the price of one year treatment with a bDMARD exceeded GPD in 26 countries. Perceived barriers for access to bDMARDs were mainly found among financial and administrative restrictions. All dimensions of access were positively correlated with the country's economic welfare (coefficients 0.69 to 0.86 for overall access scores). CONCLUSIONS: Patients with RA in lower income European countries have less access to bDMARDs and sDMARDs, with particularly striking unaffordability of bDMARDs in some of these countries. When accepting that sDMARDs and bDMARDs are equally needed across countries to treat RA, our data point to inequities in access to pharmacological treatment for RA in Europe.
Citations
Cited by
- Global recruitment patterns and placebo responses in clinical trials of rheumatoid arthritis
- Sociodemographic, disease, health system, and contextual factors affecting the initiation of biologic agents in rheumatoid arthritis: a longitudinal study. [europepmc]
- The global challenges and opportunities in the practice of rheumatology: white paper by the World Forum on Rheumatic and Musculoskeletal Diseases. [europepmc]
- Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. [europepmc]
- Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. [europepmc]
- The changing landscape of biosimilars in rheumatology. [europepmc]
- A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. [europepmc]
- Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. [europepmc]
- Inflammatory Bowel Diseases (Crohn´s Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications. [europepmc]
- The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries. [europepmc]
- Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany. [europepmc]
- The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications. [europepmc]
- Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study. [europepmc]
- Ongoing Initiatives to Improve the Quality and Efficiency of Medicine Use within the Public Healthcare System in South Africa; A Preliminary Study. [europepmc]
- Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. [europepmc]
- Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial. [europepmc]
- Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets. [europepmc]
- Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial. [europepmc]
- Treatment failure in inflammatory arthritis: time to think about syndemics? [europepmc]
- Era of biosimilars in rheumatology: reshaping the healthcare environment. [europepmc]
- Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis. [europepmc]
- The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. [europepmc]
- Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries? [europepmc]
- EULAR recommendations for a core data set for pregnancy registries in rheumatology. [europepmc]
- The Expiry of Humira ® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures. [europepmc]
- The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review. [europepmc]
Related